Cargando…

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients

BACKGROUND: Few biomarkers can predict the efficiency of PD-1 blockade in patients with hepatocellular carcinoma (HCC). This study aimed to investigate the prognostic role of AFP and PIVKA-II in HCC patients receiving anti-PD-1 immunotherapy. METHODS: A total of 235 HCC patients treated with PD-1 bl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Xuqi, Mei, Jie, Lin, Wenping, Yang, Ziliang, Peng, Wei, Chen, Jinbin, Zhang, Yaojun, Xu, Li, Chen, Minshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254996/ https://www.ncbi.nlm.nih.gov/pubmed/34218801 http://dx.doi.org/10.1186/s12885-021-08428-w

Ejemplares similares

Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population
por: Zheng, Kepu, et al.
Publicado: (2023)

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma
por: Tian, Shan, et al.
Publicado: (2022)

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
por: Feng, Honglei, et al.
Publicado: (2021)

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma
por: Lee, Qiuyan, et al.
Publicado: (2021)

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
por: Chan, Henry L Y, et al.
Publicado: (2022)

Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications
por: Sun, Xuqi, et al.
Publicado: (2022)

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
por: Xu, Fei, et al.
Publicado: (2021)

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
por: Kim, Do Young, et al.
Publicado: (2023)

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma
por: Tran, Vinh Thanh, et al.
Publicado: (2023)

Diagnostic Performance of AFP, AFP-L3, or PIVKA-II for Hepatitis C Virus-Associated Hepatocellular Carcinoma: A Multicenter Analysis
por: Liu, Siyu, et al.
Publicado: (2022)

Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients
por: Hadi, Hana, et al.
Publicado: (2022)

PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients
por: Suttichaimongkol, Tanita, et al.
Publicado: (2023)

Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma
por: Park, Hana, et al.
Publicado: (2013)

Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation
por: Si, Yuan-Quan, et al.
Publicado: (2020)

Effect of PIVKA‐II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery
por: Cai, Yunshi, et al.
Publicado: (2023)

Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy
por: Sun, Xuqi, et al.
Publicado: (2020)

Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients
por: Hu, Zili, et al.
Publicado: (2022)

Effect of prior cancer on survival of hepatocellular carcinoma: implications for clinical trial eligibility criteria
por: Sun, Xuqi, et al.
Publicado: (2021)

AFP ratio predicts HCC recurrence after liver transplantation
por: Koch, Christine, et al.
Publicado: (2020)

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma
por: Zakhary, Nadia I., et al.
Publicado: (2013)

Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve the Survival of Patients?
por: Sun, Xuqi, et al.
Publicado: (2020)

Combination of dual serum fluorescence, AFP and hepatic function tests is valuable to identify HCC in AFP-elevated liver diseases
por: Wang, Ting, et al.
Publicado: (2017)

Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases
por: Tarao, Kazuo, et al.
Publicado: (2020)

Investigation of Potential Molecular Biomarkers for Diagnosis and Prognosis of AFP-Negative HCC
por: Liu, Zijing, et al.
Publicado: (2021)

AFP Response to Locoregional Therapy Can Stratify the Risk of Tumor Recurrence in HCC Patients after Living Donor Liver Transplantation
por: Chen, I-Hsuan, et al.
Publicado: (2023)

Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients
por: Chen, Youran, et al.
Publicado: (2022)

AFP promotes HCC progression by suppressing the HuR-mediated Fas/FADD apoptotic pathway
por: Chen, Tianke, et al.
Publicado: (2020)

Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis
por: Jiang, Yingying, et al.
Publicado: (2020)

Expression of hepatitis B surface antigen in liver tissues can serve as a predictor of prognosis for hepatitis B virus-related hepatocellular carcinoma patients after liver resection
por: He, Ziming, et al.
Publicado: (2020)

Heterogeneities of Site-Specific N-Glycosylation in HCC Tumors With Low and High AFP Concentrations
por: Zhao, Ting, et al.
Publicado: (2020)

The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up?
por: Sun, Xuqi, et al.
Publicado: (2019)

AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy
por: Watanabe, Takao, et al.
Publicado: (2021)

Prognostic value of des-γ-carboxyprothrombin in patients with AFP-negative HCC treated with TACE
por: Sun, Hanyao, et al.
Publicado: (2022)

Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma
por: Yang, Zhenyun, et al.
Publicado: (2022)

Primary colon cancer with a high serum PIVKA-II level
por: Kato, Kazuya, et al.
Publicado: (2014)

PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
por: Tartaglione, Sara, et al.
Publicado: (2021)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_413ekrl5ivehus87ahd9bih8q8